学术探索
学术期刊
新闻热点
数据分析
智能评审

Stampidine is a potent inhibitor of zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations

被引：47
作者：
Uckun, FM
Pendergrass, S
Venkatachalam, TK
Qazi, S
Richman, D
机构：
[1] Parker Hughes Inst, Drug Discovery Program, Dept Virol, St Paul, MN 55113 USA
[2] Parker Hughes Inst, Drug Discovery Program, Dept Bioinformat, St Paul, MN 55113 USA
[3] Parker Hughes Inst, Drug Discovery Program, Dept Immunol, St Paul, MN 55113 USA
[4] Parker Hughes Inst, Drug Discovery Program, Dept Chem, St Paul, MN 55113 USA
[5] Parker Hughes Ctr Clin Immunol, Roseville, MN USA
[6] Univ Calif San Diego, Virol Sect, La Jolla, CA 92093 USA
[7] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
[8] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[9] VA San Diego Healthcare Syst, La Jolla, CA USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 11期
关键词：
D O I：
10.1128/AAC.46.11.3613-3616.2002
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We report the antiretroviral activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine [STAMP]), a novel aryl phosphate derivative of stavudine, against primary clinical human immunodeficiency virus type 1 (HIV-1) isolates. STAMP inhibited each one of nine clinical HIV-1 isolates of non-B envelope subtype and 20 genotypically and phenotypically nucleoside analog reverse transcriptase inhibitor-resistant HIV-1 isolates at subnanomolar to low-nanomolar concentrations.
引用
收藏
页码：3613 / 3616
页数：4
相关论文
共 19 条
[1]  
Balzarini J, 1996, MOL PHARMACOL, V50, P1207
[2]   Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives [J].
Balzarini, J ;
Karlsson, A ;
Aquaro, S ;
Perno, CF ;
Cahard, D ;
Naesens, L ;
DeClercq, E ;
McGuigan, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :7295-7299
[3]  
BALZARINI J, 1989, J BIOL CHEM, V264, P6127
[4]  
Chen CL, 2001, DRUG METAB DISPOS, V29, P1035
[5]   Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study [J].
Duwe, S ;
Brunn, M ;
Altmann, D ;
Hamouda, O ;
Schmidt, B ;
Walter, H ;
Pauli, G ;
Kücherer, C .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (03) :266-273
[6]   ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ACTIVITY OF AN ANTI-CD4 IMMUNOCONJUGATE CONTAINING POKEWEED ANTIVIRAL PROTEIN [J].
ERICE, A ;
BALFOUR, HH ;
MYERS, DE ;
LESKE, VL ;
SANNERUD, KJ ;
KUEBELBECK, V ;
IRVIN, JD ;
UCKUN, FM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :835-838
[7]   The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention [J].
Hu, DJ ;
Dondero, TJ ;
Rayfield, MA ;
George, JR ;
Schochetman, G ;
Jaffe, HW ;
Luo, CC ;
Kalish, ML ;
Weniger, BG ;
Pau, CP ;
Schable, CA ;
Curran, JW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03) :210-216
[8]   Phosphoramidate derivatives of d4T as inhibitors of HIV: The effect of amino acid variation [J].
McGuigan, C ;
Tsang, HW ;
Cahard, D ;
Turner, K ;
Velazquez, S ;
Salgado, A ;
Bidois, L ;
Naesens, L ;
DeClercq, E ;
Balzarini, J .
ANTIVIRAL RESEARCH, 1997, 35 (03) :195-204
[9]   Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells [J].
McGuigan, C ;
Cahard, D ;
Sheeka, HM ;
DeClercq, E ;
Balzarini, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (10) :1183-1186
[10]   Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite [J].
McGuigan, C ;
Cahard, D ;
Sheeka, HM ;
DeClercq, E ;
Balzarini, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (08) :1748-1753
12